Table 2.

Brain topological metrics showing differences among never-treated long-term schizophrenia patients, antipsychotic-treated patients of similar illness duration, and healthy controls

					Post-hoc LSD
	Never-treated Sch.	Antipsychotic-treated Sch.	Controls	ANOVA	Controls versus never-treated Sch.	Controls versus antipsychotic-treated Sch.	Never-treated Sch. versus treated Sch.
Measurements	Mean ± SD	Mean ± SD	Mean ± SD	p (f) value	p (d) value	p (d) value	p (d) value
Global
Lnet	0.494 ± 0.025	0.476 ± 0.027	0.468 ± 0.020	0.003* (0.397)	0.001* (1.148)	0.302	0.013* (0.692)
Eglobal	0.040 ± 0.002	0.041 ± 0.002	0.042 ± 0.002	0.008* (0.364)	0.002* (1.000)	0.257	0.035* (0.500)
Nodal efficiency
R putamen/caudate	0.035 ± 0.003	0.038 ± 0.004	0.041 ± 0.006	<0.001# (0.473)	<0.001* (1.265)	0.051	0.011* (0.849)
L putamen/caudate	0.035 ± 0.003	0.039 ± 0.003	0.040 ± 0.005	<0.001# (0.469)	<0.001* (1.213)	0.185	0.003** (1.333)
R amygdala/hippocampus	0.036 ± 0.004	0.041 ± 0.004	0.042 ± 0.006	<0.001# (0.463)	<0.001* (1.177)	0.319	0.001** (1.250)
L pre-/postcentral gyri	0.036 ± 0.005	0.038 ± 0.006	0.043 ± 0.005	<0.001# (0.476)	<0.001* (1.400)	0.004* (0.905)	0.127

L_net characteristic shortest path length, E_global global network efficiency, Sch. schizophrenia patients, ANOVA analysis of variance, LSD least significance difference, SD standard deviation, d Cohen’s d, f Cohen’s f, L left, R right

^*Significant difference of topological metrics between groups at p < 0.05

^**Significant difference of topological metrics between groups at p < 0.05 after correcting for Positive and Negative Syndrome Scale total score

^#Significant difference of topological metrics between groups at p < 0.05 after Bonferroni correction (n = 90)